Abstract:Background: As a member of annexin family proteins, annexin A3 (ANXA3) has 36-kDa and 33-kDa isoforms, which plays important roles in aggressiveness, tumorigenesis and drug resistance in tumors. Previous studies mainly focused on the role of total ANXA3 in cancers without distinguishing the distinction between the two isoforms, the role of 33-kDa ANXA3 in cancer remains unclear. Current work established the potential role and regulation mechanism of 33-kDa ANXA3 in hepatocarcinoma. Methods: The expression patterns of ANXA3, CRKL, Rac1, c-Myc and pAkt were analyzed in hepatocarcinoma specimens by western blotting; The biological function of 33-kDa ANXA3 in hepatocarcinoma cell growth, metastasis, apoptosis, angiogenesis, chemoresistance and the underlying molecular mechanism were investigated using gain-of-function strategyin vitro or in vivo. Findings: 33-kDa ANXA3 protein was significantly upregulated in cancerous tissues compared with paracancerous non-tumor liver tissues of hepatocarcinoma patients. Its stable knockdown decreased the in vivo tumor growing velocity and malignancy of hepatocarcinoma HepG2 cells transplanted in nude mice. The in vitro experimental results indicated 33-kDa ANXA3 knockdown suppressed proliferative, colony forming, migrative and invasive abilities of HepG2 cells through downregulating CRKL, Rap1b, Rac1, pMEK, pERK2 and c-Myc in ERK pathway; inhibited angiogenesis ability of HepG2 cells through inactivating PI3K/Akt-HIF pathway; induced apoptosis and enchanced chemoresistance of HepG2 cells through increasing Bax/decreasing Bcl-2 expressions and inactivating caspase 9/caspase 3 in intrinsic apoptosis pathway. Accordingly, CRKL, Rac1, c-Myc and pAkt were also upregulated in cancerous tissues compared with paracancerous non-tumor liver tissues of hepatocarcinoma patients. Interpretation: 33-kDa ANXA3 plays vital role in hepatocarcinoma malignancy, angiogenesis and chemoresistance. It is of potential use in prognosis and therapeutics for hepatocarcinoma. Funding Statement: This work was supported by grants from National Natural Science Foundation of China (81672737, 81272186, 31900517) and Natural Science Foundation of Liaoning (LZ2019003, 20181550168, LQ2017001). Declaration of Interests: The authors declare no potential conflicts of interest. Ethics Approval Statement: Tissue use and study protocol were approved by the Medical Ethics Committee of Dalian Medical University. Informed consent was obtained from each patient. All experiment methods were performed in accordance with the relevant guidelines and regulations.

Quantitative Proteome Analysis Reveals Annexin A3 As A Novel Biomarker in Lung Adenocarcinoma

Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma

Quantitative Proteomic Analysis Of Metastasis-Associated Proteins In Human Primary Lung Adenocarcinoma

P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adenocarcinoma

Wnt3a Expression Is Associated with Epithelial-Mesenchymal Transition and Impacts Prognosis of Lung Adenocarcinoma Patients.

Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in Cancer

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

NPM3 As a Novel Oncogenic Factor and Poor Prognostic Marker Contributes to Cell Proliferation and Migration in Lung Adenocarcinoma

Quantitative Proteomic Profiling the Molecular Signatures of Annexin A5 in Lung Squamous Carcinoma Cells

ANCCA Protein Expression is a Novel Independent Poor Prognostic Marker in Surgically Resected Lung Adenocarcinoma

Elevated Serum Annexin A1 As Potential Diagnostic Marker for Lung Cancer: a Retrospective Case-Control Study.

Quantitative proteomics identified circulating biomarkers in lung adenocarcinoma diagnosis

Bioinformatics and Experimental Approach Identify Lipocalin 2 As a Diagnostic and Prognostic Indicator for Lung Adenocarcinoma

Identification of Flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis

Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma

Annexin A1 is a Potential Biomarker of Bone Metastasis in Small Cell Lung Cancer

Identification of Three Lncrnas As Potential Predictive Biomarkers of Lung Adenocarcinoma

[Proteomic Study of Gallbladder Cancer, with Special Reference on the Expression and Significance of Annexin A3].

33-kDa ANXA3 Knockdown Suppresses Carcinogenesis, Angiogenesis and Enhances Chemoresistance of Hepatocarcinoma via Inhibiting ERK, PI3K/Akt-HIF and Intrinsic Apoptosis Pathways

Annexin-1 Downregulation is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma